文献速递主动脉疾病

既往胸主动脉修复不影响TEVAR术后不良结局

Previous thoracic aortic repair is not associated with adverse outcomes after thoracic endovascular aortic repair.
PubMed 文献 · J Vasc Surg · 2019-10-13

基于VQI数据库2012-2018年4010例TEVAR患者,比较既往升主动脉/弓部修复(470例)、降胸主动脉修复(132例)与无既往修复(3408例)三组。结果显示30天死亡率(4%、6%、6%,P=.17)和脊髓缺血发生率(3%、3%、3.8%,P=.65)无显著差异,既往胸主动脉修复未增加TEVAR术后不良风险。

要点

  • 既往胸主动脉修复者TEVAR术后30天死亡率和脊髓缺血风险与无修复者相当。
  • 呼吸并发症在无既往修复组最高(11% vs 9% vs 4%,P=.034)。
  • 术后住院时间无既往修复组最长(9.6±19.4天 vs 8.2±18.3天 vs 5.9±8.6天,P=.038)。

核心结论

  • 既往胸主动脉修复与TEVAR术后脊髓缺血或30天死亡率风险增加无关。

研究设计与样本

  • 回顾性队列研究,查询SVS VQI数据库2012-2018年TEVAR病例,排除既往腹主动脉修复、TEVAR超过5区及脊髓缺血数据缺失者,最终纳入4010例,分为既往升主动脉/弓部修复组(470例)、既往降胸主动脉修复组(132例)和无既往修复组(3408例)。

主要发现

  • 30天死亡率:组1为4%(19/470),组2为6%(8/132),组3为6%(213/3408),P=.17。
  • 脊髓缺血发生率:组1为3%(14/470),组2为3%(4/132),组3为3.8%(128/3408),P=.65。
  • 卒中、再干预、心肌梗死和心脏并发症在三组间无显著差异。
  • 呼吸并发症发生率组3最高(11%,360/3408),组1为9%(44/470),组2为4%(5/132),P=.034。
  • 术后住院时间组3最长(9.6±19.4天),组1为8.2±18.3天,组2为5.9±8.6天,P=.038。

关键数值与推荐

  • 30天死亡率的独立预测因素包括:术中输注浓缩红细胞单位数、急诊或紧急修复、年龄较大、血清肌酐水平升高、无法自理、总手术时间、术中左锁骨下动脉闭塞、远端支架着陆区5区及糖尿病。
  • 脊髓缺血的预测因素包括:总手术时间、急诊和紧急修复以及血清肌酐水平升高。

临床怎么用

  • 对于既往接受过胸主动脉修复的患者,TEVAR术后脊髓缺血和30天死亡风险与无修复史者相似,不应因既往修复史而限制TEVAR。
  • 应关注术中输血、急诊手术、肾功能、手术时间及左锁骨下动脉覆盖等可调控因素以降低死亡和脊髓缺血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As many as 20% of patients who have undergone previous thoracic aortic repair will require reintervention, which could entail thoracic endovascular aortic repair (TEVAR). A paucity of data is available on mortality and the incidence of spinal cord ischemia (SCI) and other postoperative complications associated with TEVAR after previous aortic repairs exclusive to the thoracic aorta. The aim of the present study was to assess the effect of previous thoracic aortic repair on the 30-day mortality and SCI outcomes for patients after TEVAR. METHODS: The Society for Vascular Surgery Vascular Quality Initiative database was queried for all cases of TEVAR from 2012 to 2018. Patients were excluded if they had undergone previous abdominal aortic repair, the TEVAR had extended beyond aortic zone 5, or SCI data were missing. The 3 cohorts compared were TEVAR with previous ascending aortic or aortic arch repair (group 1), TEVAR with previous descending thoracic aortic repair (group 2), and TEVAR without previous repair (group 3). The primary outcomes of interest were 30-day mortality and SCI. The secondary outcomes included stroke, myocardial infarction, cardiac complications, respiratory complications, postoperative length of stay, and reintervention. The patient variables were compared using χ2 tests, analysis of variance, or Kruskal-Wallis tests, as appropriate. Logistic regression analysis was performed to identify the predictors of 30-day mortality and SCI. RESULTS: A total of 4010 patients met the inclusion criteria, with 470 in group 1, 132 in group 2, and 3408 in group 3. The 30-day mortality was 4% (19 of 470) in group 1, 6% (8 of 132) in group 2, and 6% (213 of 3408) in group 3 (P = .17). The incidence of SCI was 3% (14 of 470) in group 1, 3% (4 of 132) in group 2, and 3.8% (128 of 3408) in group 3 (P = .65). Stroke, reintervention, myocardial infarction, and cardiac complications were not significantly different among the 3 groups. The incidence of respiratory complications was greatest for group 3 (11%; 360 of 3408) compared with groups 1 (9%; 44 of 470) and 2 (4%; 5 of 132; P = .034). Similarly, the postoperative length of stay was longest for group 3 (9.6 ± 19.4 days vs 8.2 ± 18.3 days for group 1 and 5.9 ± 8.6 days for group 2; P = .038). The independent predictors of 30-day mortality for all TEVAR patients included units of packed red blood cells transfused intraoperatively, urgent or emergent repairs, older age, increasing serum creatinine level, inability to perform self-care, total procedure time, occlusion of the left subclavian artery intraoperatively, distal endograft landing zone 5, and diabetes. The predictors of SCI included the total procedure time, urgent and emergent repairs, and increasing serum creatinine level. CONCLUSIONS: TEVAR after previous thoracic aortic repair was not associated with an increased risk of SCI or 30-day mortality compared with TEVAR without previous aortic repair.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. King RW, Wooster MD, Ruddy JM, et al. Previous thoracic aortic repair is not associated with adverse outcomes after thoracic endovascular aortic repair. J Vasc Surg. 2019. PMID: 31619351. doi:10.1016/j.jvs.2019.07.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。